MicroRNA-125a-3p Modulate Amyloid β-Protein through the MAPK Pathway in Alzheimer’s Disease

Author:

Zhu Xi-Chen1234,Zhu Meng-Zhuo3,Lu Jing4,Yao Qing-Yu1,Hu Jia-Wei1,Long Wen-Jun1,Ruan Sha-Sha12,Dai Wen-Zhuo12,Li Rong35

Affiliation:

1. Department of Neurology, the Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu Province, China

2. Brain Institue, Jiangnan University, Wuxi, Jiangsu Province, China

3. Department of Neurology, the Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu Province, China

4. Department of Neurology, the Affiliated Wuxi No. 2 People's Hospital of Nanjing Medical University, Wuxi, Jiangsu Province, China

5. Department of Pharmacy, the Affiliated Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu Province, China

Abstract

Background: MicroRNA (miR)-125a-3p is reported to play an important role in some central nervous system diseases, such as Alzheimer’s disease (AD). However, a study has not been conducted on the mechanism of miR-125a-3p in the pathological process of AD. Methods: First, we assessed the expression of miR-125a-3p in AD cohort. Subsequently, we altered the expressions of miR-125a-3p to assess its role in cell viability, cell apoptosis, amyloid-β (Aβ) metabolism, and synaptic activity. Finally, we identified its potential mechanism underlying AD pathology. Results: This study unveiled the potential function of miR-125a-3p through modulating amyloid precursor protein processing. Additionally, miR-125a-3p influenced cell survival and activated synaptic expression through the modulation of Aβ metabolism in the mitogen-activated protein kinase (MAPK) pathway via fibroblast growth factor receptor 2. Conclusion: Our study indicates that targeting miR-125a-3p may be an applicable therapy for AD in the future. However, more in vitro and in vivo studies with more samples are needed to confirm these results.

Funder

National Natural Science Foundation of China

National Natural Science Foundation of Jiangsu Province

Wuxi Top Talent Support Program for young and middle-aged people of Wuxi Health Committee

Wuxi Municipal Health and Family Planning Commission Fund

Publisher

Bentham Science Publishers Ltd.

Subject

Neurology (clinical),Neurology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3